Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL

被引：0
|
作者：
Yin, C [1 ]
Luthra, R [1 ]
Cortes, J [1 ]
Reeves, N [1 ]
Hayes, K [1 ]
Glassman, A [1 ]
Kantarjian, H [1 ]
Jones, D [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2004年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
H8
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [1] Induction of BCR-ABL mutations for acquired resistance in chronic myelogenous leukemia cells by imatinib
    Yuan, Hongfeng
    Gao, Chunggang
    Bhatia, Ravi
    Chen, WenYong
    CANCER RESEARCH, 2009, 69
  • [2] BCR-ABL duplication revealed by fish analysis is frequently associated with imatinib resistance in chronic phase chronic myelogenous leukemia patients
    Rousselot, Ph.
    Mossafa, H.
    Joha, S.
    Tigaud, I.
    Rea, D.
    Corm, S.
    Hayette, S.
    Cayuela, J. M.
    Maarek, O.
    Roche-Lestienne, C.
    Terre, C.
    Lev, V.
    Preudhomme, C.
    Michallet, M.
    Calvo, F.
    Nicolini, F.
    Rousselot, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 356 - 357
  • [3] Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
    Donato, NJ
    Wu, JY
    Stapley, J
    Lin, H
    Arlinghaus, R
    Aggarwal, B
    Shishodin, S
    Albitar, M
    Hayes, K
    Kantarjian, H
    Talpaz, M
    CANCER RESEARCH, 2004, 64 (02) : 672 - 677
  • [4] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [5] BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia
    Schiffer, Charles A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 258 - 265
  • [6] BCR-ABL TYROSINE KINASE DOMAIN MUTATIONS COMBINATIONS AFFECTS IMATINIB RESISTENCE IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
    Bintoro, S. U. Y.
    Amrita, P. N. A.
    Joewarini, E.
    Suryohusodo, P.
    Soebandiri, S.
    NEW ARMENIAN MEDICAL JOURNAL, 2019, 13 (04): : 53 - 58
  • [7] BCR- ABL KINASE MUTATIONS TO IMATINIB RESISTANCE IN CHRONIC MYELOID LEUKEMIA
    Thungappa, S. Chiradoni
    Singh, T.
    Rashmi, N. R.
    Lokanatha, D.
    Rajshekar, H.
    Lakshmaiah, K. C.
    Babu, K. G.
    Suresh, T. M.
    ANNALS OF ONCOLOGY, 2010, 21 : 357 - 357
  • [8] Management of imatinib mesylate-resistances induced by BCR-ABL mutations in chronic myelogenous leukemia
    Nicolini, Franck-Emmanuel
    Ducastelle, Sophie
    Corm, Selim
    HEMATOLOGIE, 2007, 13 (06): : 457 - 464
  • [9] BCR-ABL kinase domain mutations in patient with secondary but not primary resistance to imatinib.
    Al-Ali, HK
    Lange, T
    Krahl, R
    Mueller, C
    Patzer, G
    Niederwieser, D
    Deininger, MWN
    BLOOD, 2002, 100 (11) : 368A - 369A
  • [10] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
12345